Wenjing Kang

机构：China Pharmaceutical University, Medicina, State Key Laboratory of Natural Medicine

发表论文 10 篇 · 总被引 72 次 · h-index 6

代表论文

• Discovery of 1 H -Imidazo[4,5- b ]pyridine Derivatives as Potent and Selective BET Inhibitors for the Management of Neuropathic Pain (2023 · Journal of Medicinal Chemistry · 被引 15)
• Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis (2023 · European Journal of Medicinal Chemistry · 被引 14)
• Targeting m6A binding protein YTHDFs for cancer therapy (2023 · Bioorganic & Medicinal Chemistry · 被引 14)
• Multi-Water Bridges Enable Design of BET BD1-Selective Inhibitors for Pancreatic Cancer Therapy (2025 · Journal of Medicinal Chemistry · 被引 11)
• Supramolecular Host–Guest Assemblies for Tunable and Modular Lysosome‐Targeting Protein Degradation (2025 · Angewandte Chemie International Edition · 被引 8)
• Rational Design of Novel Quinazolinone–Pyrrolodihydropyrrolone Analogs as PIM/HDAC Dual-Target Inhibitors for the Treatment of Acute Myelocytic Leukemia (2025 · Journal of Medicinal Chemistry · 被引 8)